@article{10.37349/etat.2025.1002347,
abstract = {Immune checkpoint inhibitors (ICIs) are established treatments for various malignancies, including lung, kidney, and colorectal cancers. However, their broad use has led to an increase in immune-related adverse events (irAEs), with thyroiditis, colitis, and pneumonitis being the most common. Hemophagocytic lymphohistiocytosis (HLH) is a rare but severe irAE characterized by excessive immune activation, leading to systemic inflammation and multi-organ dysfunction. We present three cases of ICI-induced HLH in patients with lung cancer who were treated with ICIs. All patients showed elevated inflammatory markers and responded to high-dose corticosteroids without the addition of etoposide. These cases underscore the importance of early recognition and treatment of HLH in patients receiving ICIs to mitigate morbidity and mortality. Large-scale studies are needed to establish standardized guidelines for diagnosing and managing ICI-induced HLH.},
author = {Khan, Abdul Wali and Chandra, Simran and Mahadevia, Himil and Subramanian, Janakiraman and Ponvilawan, Ben and Bansal, Dhruv},
doi = {10.37349/etat.2025.1002347},
journal = {Exploration of Targeted Anti-tumor Therapy},
elocation-id = {1002347},
title = {Immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in lung cancer: a case series},
url = {https://www.explorationpub.com/Journals/etat/Article/1002347},
volume = {6},
year = {2025}
}